These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35569559)

  • 41. A biocompatible reverse thermoresponsive polymer for ocular drug delivery.
    Balachandra A; Chan EC; Paul JP; Ng S; Chrysostomou V; Ngo S; Mayadunne R; van Wijngaarden P
    Drug Deliv; 2019 Dec; 26(1):343-353. PubMed ID: 30905169
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.
    Mandal A; Bisht R; Rupenthal ID; Mitra AK
    J Control Release; 2017 Feb; 248():96-116. PubMed ID: 28087407
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy.
    Yilmaz T; Cordero-Coma M; Lavaque AJ; Gallagher MJ; Padula WV
    Curr Pharm Biotechnol; 2011 Mar; 12(3):337-46. PubMed ID: 20939800
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
    Emerson MV; Lauer AK
    BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration.
    Adamis AP; de Juan E
    Curr Opin Ophthalmol; 2022 May; 33(3):131-136. PubMed ID: 35266895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Challenges and opportunities for drug delivery to the posterior of the eye.
    Cabrera FJ; Wang DC; Reddy K; Acharya G; Shin CS
    Drug Discov Today; 2019 Aug; 24(8):1679-1684. PubMed ID: 31175955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ocular Drug Delivery: Present Innovations and Future Challenges.
    Gote V; Sikder S; Sicotte J; Pal D
    J Pharmacol Exp Ther; 2019 Sep; 370(3):602-624. PubMed ID: 31072813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-acting intraocular Delivery strategies for biological therapy of age-related macular degeneration.
    Iyer S; Radwan AE; Hafezi-Moghadam A; Malyala P; Amiji M
    J Control Release; 2019 Feb; 296():140-149. PubMed ID: 30660630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanotherapies for the Treatment of Age-Related Macular Degeneration (AMD) Disease: Recent Advancements and Challenges.
    Rapalli VK; Gorantla S; Waghule T; Mahmood A; Singh PP; Dubey SK; Saha RN; Singhvi G
    Recent Pat Drug Deliv Formul; 2019; 13(4):283-290. PubMed ID: 31951173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug Delivery to the Posterior Segment of the Eye.
    Moisseiev E; Loewenstein A
    Dev Ophthalmol; 2017; 58():87-101. PubMed ID: 28351054
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nanomedicine and drug delivery to the retina: current status and implications for gene therapy.
    Tawfik M; Chen F; Goldberg JL; Sabel BA
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Dec; 395(12):1477-1507. PubMed ID: 36107200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent perspectives in ocular drug delivery.
    Gaudana R; Jwala J; Boddu SH; Mitra AK
    Pharm Res; 2009 May; 26(5):1197-216. PubMed ID: 18758924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations.
    Varela-Fernández R; Díaz-Tomé V; Luaces-Rodríguez A; Conde-Penedo A; García-Otero X; Luzardo-Álvarez A; Fernández-Ferreiro A; Otero-Espinar FJ
    Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32188045
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug delivery to the posterior segment of the eye.
    Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
    Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Light-responsive in situ forming injectable implants for effective drug delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Chen YS; Jin J; Rupenthal ID
    Expert Opin Drug Deliv; 2016 Jul; 13(7):953-62. PubMed ID: 26967153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration.
    Du JD; Fong WK; Caliph S; Boyd BJ
    Drug Deliv Transl Res; 2016 Dec; 6(6):781-792. PubMed ID: 27194165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging Treatment Modalities for Neovascular Age-Related Macular Degeneration: A Systematic Overview.
    Balatsoukas DD; Tsaousis KT; Boboridis KG; Konstas AG; Topouzis F
    Adv Ther; 2022 Jan; 39(1):5-32. PubMed ID: 34724151
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug delivery to the posterior segment of the eye for pharmacologic therapy.
    Shah SS; Denham LV; Elison JR; Bhattacharjee PS; Clement C; Huq T; Hill JM
    Expert Rev Ophthalmol; 2010 Feb; 5(1):75-93. PubMed ID: 20305803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A review of neovascular glaucoma. Etiopathogenesis and treatment.
    Dumbrăveanu L; Cușnir V; Bobescu D
    Rom J Ophthalmol; 2021; 65(4):315-329. PubMed ID: 35087972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug delivery to the posterior segment of the eye.
    Kuppermann BD; Loewenstein A
    Dev Ophthalmol; 2010; 47():59-72. PubMed ID: 20703044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.